MeiraGTx (MGTX)
Develops locally delivered AAV gene therapies and manufactures its own viral vectors.
Something off on this page? Send us feedback.
Develops AAV-based gene therapies for eye, brain and salivary-gland disease, paired with a riboswitch platform that lets patients control transgene activity with an oral pill. Vector and plasmid manufacturing happen in owned GMP plants rather than through outside contractors, an unusual setup for a company at this stage.
Builds gene therapies delivered locally to the eye, central nervous system and salivary glands using adeno-associated virus vectors, paired with a riboswitch technology that turns transgene expression on and off with an oral pill.
Manufacturing stays in-house at owned GMP-licensed viral-vector and plasmid plants in London and Shannon, Ireland, rather than outsourced to contract manufacturers, a structure most peers its size do not attempt.
No product has reached approval yet, so revenue comes from collaboration and licensing payments tied to partnered programs, including a major pharmaceutical partner and a joint venture funding late-stage neurology and metabolic-disease work. Corporate operations sit in New York; research and manufacturing sit in the UK and Ireland.
A lead retinal-disease program was sold to a partner and later reacquired after a late-stage trial missed its primary goal, with regulatory filings now planned in multiple markets.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 8, 2026 | RBC Capital | Reiterate | Rating: —Target: $24 | Target: $26 |
| Apr 17, 2026 | RBC Capital | Reiterate | Rating: —Target: $16 | Target: $24 |
| Mar 27, 2026 | Piper Sandler | Reiterate | Rating: —Target: — | Target: $26 |
| Nov 24, 2025 | H.C. Wainwright | Target | Target: — | Target: $20 |
| Nov 14, 2025 | RBC Capital | Reiterate | Rating: —Target: $9 | Target: $16 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $143.2M · Total debt $112.3M · Total assets $396.4M · Shareholders' equity $215.6M
- Revenue
- $321.4M
- Operating income
- $244.4M
- Net income
- $160.7M
No dividends on record.
| Institutions | ≈ 82.30% | 79.04M shares | |
|---|---|---|---|
| 162 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.03% | 1.95M shares | |
| 5 holders · as of Jul 21, 2026 | |||
| Other | ≈ 15.67% | 15.05M shares | |
| remainder | |||
96.04M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
SanofiInstitution | 12.70% | 12.20M | as of Jun 30, 2026 |
Perceptive Advisors LLCInstitution | 11.23% | 10.79M | as of Jun 30, 2026 |
Rubric Capital Management LPInstitution | 9.47% | 9.10M | as of Jun 30, 2026 |
Johnson & JohnsonInstitution | 6.91% | 6.64M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 4.95% | 4.76M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 18, 2026 | Alexandria Forbes | director, officer: PRESIDENT & CEO | −62,000 | $13.86 |
| Jul 21, 2026 | Richard Giroux | officer: CFO & COO | −56,000 | $12.51 |
| Jul 7, 2026 | Stuart Naylor | officer: CHIEF SCI OFCR, OPHTHALMOLOGY | −27,659 | $14.80 |
| May 19, 2026 | Alexandria Forbes | director, officer: PRESIDENT & CEO | −62,000 | $9.17 |
| Apr 21, 2026 | Richard Giroux | officer: CFO & COO | −56,000 | $10.22 |
- uniQure
Rival CNS AAV gene therapy leader; abandoned the vertical-manufacturing model.
- REGENXBIO
AAV vector platform licensor and direct ocular AAV rival with own manufacturing.
- Voyager Therapeutics
CNS AAV capsid rival with a partnered Parkinson's gene therapy program.
- Sarepta Therapeutics
Commercial AAV gene therapy leader in Duchenne; bellwether on AAV safety.
- 4D Molecular Therapeutics
Rival AAV capsid platform; former program shared the same RPGR gene target.
- Ocugen
Gene-agnostic AAV therapy for RP racing toward the same XLRP patients.
- Krystal Biotech
Commercial redosable gene therapy peer with a growing ocular pipeline.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MeiraGTx | $12.15 | −1.59% | $1.14B | 17.4 | — | 2.9 | +8,608.6% |
| uniQure | $43.87 | −3.11% | $3.14B | — | — | 168.2 | +11.0% |
| REGENXBIO | $8.00 | −1.84% | $421.3M | — | — | 2.4 | +405.7% |
| Voyager Therapeutics | $3.07 | −2.39% | $189.7M | — | — | 5.5 | −39.1% |
| Sarepta Therapeutics | $20.43 | −1.83% | $2.20B | — | 35.5 | 1.1 | −34.3% |
| 4D Molecular Therapeutics | $15.41 | −2.96% | $830.1M | — | — | 9.0 | +25,106.7% |
| Ocugen | $1.02 | −2.40% | $352.7M | — | — | 77.0 | +8.4% |
| Krystal Biotech | $349.32 | −0.44% | $10.34B | 44.0 | 41.1 | 23.5 | +24.1% |
| Median | 44.0 | 38.3 | 9.0 | +11.0% |